Published in Drug Metab Dispos on February 24, 2011
Role of intestinal cytochrome p450 enzymes in diclofenac-induced toxicity in the small intestine. J Pharmacol Exp Ther (2012) 0.90
Potential biological functions of cytochrome P450 reductase-dependent enzymes in small intestine: novel link to expression of major histocompatibility complex class II genes. J Biol Chem (2012) 0.90
NADPH-cytochrome P450 oxidoreductase: roles in physiology, pharmacology, and toxicology. Drug Metab Dispos (2012) 0.88
TRAM-34, a putatively selective blocker of intermediate-conductance, calcium-activated potassium channels, inhibits cytochrome P450 activity. PLoS One (2013) 0.78
Mice deficient in intestinal epithelium cytochrome P450 reductase are prone to acute toxin-induced mucosal damage. Sci Rep (2014) 0.78
Novel effects of simvastatin on uterine fibroid tumors: in vitro and patient-derived xenograft mouse model study. Am J Obstet Gynecol (2015) 0.77
Regulation of intestinal cytochrome P450 expression by hepatic cytochrome P450: possible involvement of fibroblast growth factor 15 and impact on systemic drug exposure. Mol Pharmacol (2013) 0.76
Intestinal epithelium-specific knockout of the cytochrome P450 reductase gene exacerbates dextran sulfate sodium-induced colitis. J Pharmacol Exp Ther (2015) 0.76
An update on the role of intestinal cytochrome P450 enzymes in drug disposition. Acta Pharm Sin B (2016) 0.75
Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res (2005) 4.13
Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol (2005) 3.56
Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol (2002) 2.74
Grapefruit juice-drug interactions. Br J Clin Pharmacol (1998) 2.68
The human intestinal cytochrome P450 "pie". Drug Metab Dispos (2006) 2.31
Grapefruit-drug interactions: can interactions with drugs be avoided? J Clin Pharmacol (2006) 1.82
Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother (1996) 1.74
Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther (1998) 1.49
Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest (2007) 1.41
6',7'-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin Pharmacol Ther (1999) 1.25
Characterization of mouse small intestinal cytochrome P450 expression. Drug Metab Dispos (2003) 1.23
Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos (2004) 1.18
Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys (1991) 1.14
An intestinal epithelium-specific cytochrome P450 (P450) reductase-knockout mouse model: direct evidence for a role of intestinal p450s in first-pass clearance of oral nifedipine. Drug Metab Dispos (2008) 1.13
The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism? Clin Pharmacokinet (2002) 1.11
The small intestine as a xenobiotic-metabolizing organ. Drug Metab Dispos (2003) 1.08
Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol (2004) 1.06
Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur J Pharm Sci (2000) 1.05
Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev (1999) 1.01
The physiological disposition of lovastatin. Drug Metab Dispos (1989) 1.00
Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos (1999) 0.98
A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metab Dispos (2001) 0.98
Quantitative determination of pravastatin and its biotransformation products in human serum by turbo ion spray LC/MS/MS. J Pharm Biomed Anal (2000) 0.97
The role of small-intestinal P450 enzymes in protection against systemic exposure of orally administered benzo[a]pyrene. J Pharmacol Exp Ther (2010) 0.92
Rat small intestinal cytochromes P450 probed by warfarin metabolism. Mol Pharmacol (1993) 0.87
Biotransformation of lovastatin. I. Structure elucidation of in vitro and in vivo metabolites in the rat and mouse. Drug Metab Dispos (1990) 0.85
Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin. J Pharmacol Exp Ther (1999) 0.82
Determination of lovastatin hydroxy acid in female B6C3F1 mouse serum. J Anal Toxicol (2008) 0.79
A rapid and specific approach for direct measurement of pravastatin concentration in plasma by LC-MS/MS employing solid-phase extraction. Biomed Chromatogr (2007) 0.78
Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase. J Biol Chem (2003) 1.88
In vivo mechanisms of tissue-selective drug toxicity: effects of liver-specific knockout of the NADPH-cytochrome P450 reductase gene on acetaminophen toxicity in kidney, lung, and nasal mucosa. Mol Pharmacol (2004) 1.30
CYP2A13: variable expression and role in human lung microsomal metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. J Pharmacol Exp Ther (2007) 1.22
Quercetin and allopurinol ameliorate kidney injury in STZ-treated rats with regulation of renal NLRP3 inflammasome activation and lipid accumulation. PLoS One (2012) 1.21
Transgenic mice with a hypomorphic NADPH-cytochrome P450 reductase gene: effects on development, reproduction, and microsomal cytochrome P450. J Pharmacol Exp Ther (2004) 1.19
Conditional knockout of the mouse NADPH-cytochrome p450 reductase gene. Genesis (2003) 1.09
Evaluation of the International Vehicle Emission (IVE) model with on-road remote sensing measurements. J Environ Sci (China) (2007) 1.08
The small intestine as a xenobiotic-metabolizing organ. Drug Metab Dispos (2003) 1.08
Metabolic activation of the tobacco carcinogen 4-(methylnitrosamino)-(3-pyridyl)-1-butanone by cytochrome P450 2A13 in human fetal nasal microsomes. Chem Res Toxicol (2005) 1.04
Generation and characterization of a Cyp2f2-null mouse and studies on the role of CYP2F2 in naphthalene-induced toxicity in the lung and nasal olfactory mucosa. J Pharmacol Exp Ther (2011) 1.03
Expression of cytochrome p450 and other biotransformation genes in fetal and adult human nasal mucosa. Drug Metab Dispos (2005) 1.02
Effects of 8-methoxypsoralen on cytochrome P450 2A13. Carcinogenesis (2004) 1.00
Genetic polymorphisms of the human CYP2A13 gene: identification of single-nucleotide polymorphisms and functional characterization of an Arg257Cys variant. J Pharmacol Exp Ther (2002) 1.00
Characterization of CYP2A13*2, a variant cytochrome P450 allele previously found to be associated with decreased incidences of lung adenocarcinoma in smokers. Drug Metab Dispos (2008) 0.94
Immunoblot analysis and immunohistochemical characterization of CYP2A expression in human olfactory mucosa. Biochem Pharmacol (2003) 0.92
The role of small-intestinal P450 enzymes in protection against systemic exposure of orally administered benzo[a]pyrene. J Pharmacol Exp Ther (2010) 0.92
Generation and characterization of a novel Cyp2a(4/5)bgs-null mouse model. Drug Metab Dispos (2012) 0.92
Reactive oxygen species-induced TXNIP drives fructose-mediated hepatic inflammation and lipid accumulation through NLRP3 inflammasome activation. Antioxid Redox Signal (2015) 0.90
Role of CYP2A5 in the bioactivation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in mice. J Pharmacol Exp Ther (2012) 0.90
Potential biological functions of cytochrome P450 reductase-dependent enzymes in small intestine: novel link to expression of major histocompatibility complex class II genes. J Biol Chem (2012) 0.90
Role of intestinal cytochrome p450 enzymes in diclofenac-induced toxicity in the small intestine. J Pharmacol Exp Ther (2012) 0.90
Generation and characterization of a CYP2A13/2B6/2F1-transgenic mouse model. Drug Metab Dispos (2012) 0.90
Targeted disruption of the olfactory mucosa-specific Cyp2g1 gene: impact on acetaminophen toxicity in the lateral nasal gland, and tissue-selective effects on Cyp2a5 expression. J Pharmacol Exp Ther (2003) 0.89
NADPH-cytochrome P450 oxidoreductase: roles in physiology, pharmacology, and toxicology. Drug Metab Dispos (2012) 0.88
A novel defensive mechanism against acetaminophen toxicity in the mouse lateral nasal gland: role of CYP2A5-mediated regulation of testosterone homeostasis and salivary androgen-binding protein expression. Mol Pharmacol (2011) 0.88
Generation of a mouse model with a reversible hypomorphic cytochrome P450 reductase gene: utility for tissue-specific rescue of the reductase expression, and insights from a resultant mouse model with global suppression of P450 reductase expression in extrahepatic tissues. J Pharmacol Exp Ther (2010) 0.86
Hepatoprotective effects of baicalein against CCl₄-induced acute liver injury in mice. World J Gastroenterol (2012) 0.85
Respective roles of CYP2A5 and CYP2F2 in the bioactivation of 3-methylindole in mouse olfactory mucosa and lung: studies using Cyp2a5-null and Cyp2f2-null mouse models. Drug Metab Dispos (2012) 0.84
Mechanisms of differential expression of the CYP2A13 7520C and 7520G alleles in human lung: allelic expression analysis for CYP2A13 heterogeneous nuclear RNA, and evidence for the involvement of multiple cis-regulatory single nucleotide polymorphisms. Pharmacogenet Genomics (2009) 0.83
Potent mutagenicity of 3-methylindole requires pulmonary cytochrome P450-mediated bioactivation: a comparison to the prototype cigarette smoke mutagens B(a)P and NNK. Chem Res Toxicol (2010) 0.82
Single nucleotide polymorphisms of the human cyp2a13 gene: evidence for a null allele. Drug Metab Dispos (2003) 0.82
Impaired hypothalamic insulin signaling in CUMS rats: restored by icariin and fluoxetine through inhibiting CRF system. Psychoneuroendocrinology (2012) 0.82
[The relationship of MMP-9, VEGF and PCNA expressions and their clinical significance in gastric adenocarcinoma]. Zhonghua Nei Ke Za Zhi (2009) 0.81
Generation and characterization of a transgenic mouse model with hepatic expression of human CYP2A6. Biochem Biophys Res Commun (2005) 0.80
Role of hepatic and intestinal p450 enzymes in the metabolic activation of the colon carcinogen azoxymethane in mice. Chem Res Toxicol (2014) 0.80
Bioactivation of the nasal toxicant 2,6-dichlorobenzonitrile: an assessment of metabolic activity in human nasal mucosa and identification of indicators of exposure and potential toxicity. Chem Res Toxicol (2013) 0.79
Expression of the rat CYP2A3 gene in transgenic mice. Drug Metab Dispos (2002) 0.79
TRAM-34, a putatively selective blocker of intermediate-conductance, calcium-activated potassium channels, inhibits cytochrome P450 activity. PLoS One (2013) 0.78
Dietary regulation of mouse intestinal P450 expression and drug metabolism. Drug Metab Dispos (2012) 0.78
The effect of ritonavir on human CYP2B6 catalytic activity: heme modification contributes to the mechanism-based inactivation of CYP2B6 and CYP3A4 by ritonavir. Drug Metab Dispos (2013) 0.78
Expression of p-Akt and COX-2 in gastric adenocarcinomas and adenovirus mediated Akt1 and COX-2 ShRNA suppresses SGC-7901 gastric adenocarcinoma and U251 glioma cell growth in vitro and in vivo. Technol Cancer Res Treat (2009) 0.77
Quercetin Protects against Cadmium-Induced Renal Uric Acid Transport System Alteration and Lipid Metabolism Disorder in Rats. Evid Based Complement Alternat Med (2012) 0.77
Regulation of intestinal cytochrome P450 expression by hepatic cytochrome P450: possible involvement of fibroblast growth factor 15 and impact on systemic drug exposure. Mol Pharmacol (2013) 0.76
Essential role of the cytochrome P450 enzyme CYP2A5 in olfactory mucosal toxicity of naphthalene. Drug Metab Dispos (2013) 0.76
Bioactivation of the cancer chemopreventive agent tamoxifen to quinone methides by cytochrome P4502B6 and identification of the modified residue on the apoprotein. Drug Metab Dispos (2012) 0.76
Anomalous pancreaticobiliary junction: image analysis and treatment principles. Hepatobiliary Pancreat Dis Int (2004) 0.75
A highly sensitive and recyclable SERS substrate based on Ag-nanoparticle-decorated ZnO nanoflowers in ordered arrays. Dalton Trans (2015) 0.75
[Experimental investigation of quantitatively analysing trace Mo in complex metallic alloys by laser induced breakdown spectroscopy]. Guang Pu Xue Yu Guang Pu Fen Xi (2011) 0.75
Suppression of Akt1 expression by small interference RNA inhibits SGC7901 cell growth in vitro and in vivo. Oncol Rep (2009) 0.75
[Inhibitory effect of adenovirus-mediated short hairpin RNA targeting P85 and Akt1 on growth of human gastric adenocarcinoma cell]. Zhonghua Nei Ke Za Zhi (2009) 0.75
[Expression of human beta-defensin 2 and tumor necrosis factor-A in colonic mucosae of ulcerative colitis and diarrhea-predominant irritable bowel syndrome]. Zhonghua Yi Xue Za Zhi (2008) 0.75